|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,226,614: Scope, Claims, and Patent Landscape
What does US Patent 7,226,614 cover?
US Patent 7,226,614, awarded on July 31, 2007, to Merck & Co., Inc., covers a method for treating viral infections using a specific class of compounds. The patent primarily claims methods of administering non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.
Key details:
- Title: Methods for the Treatment of Viral Infections
- Assignee: Merck & Co., Inc.
- Filing Date: October 24, 2003
- Issue Date: July 31, 2007
- Expiration Date: July 31, 2025 (assuming no extensions or terminal disclaimers)
What are the main claims?
Core claims:
- Claim 1: Outlines a method of treating HIV-1 infection in a subject by administering a compound of Formula I, where the structure is a specific NNRTI with defined substituents.
- Claims 2-10: Specify particular substituents, pharmaceutical compositions, dosing regimens, and methods of use involving compounds within the scope of Formula I.
- Claims 11-20: Cover methods of synthesis and intermediates used to prepare the compounds.
Claim hierarchy:
- Use claims: Cover treating HIV-1 with the compounds.
- Composition claims: Asserts the pharmaceutical formulations containing the compounds.
- Method claims: Encompasses synthesis and administration protocols.
Claim scope:
- The claims are centered on compounds with a core structure of a specified heterocyclic system.
- Variations include different substituents at particular positions, broadening the scope to cover multiple derivatives.
- The patent particularly emphasizes the compounds' efficacy, including activity against resistant HIV strains.
Patent landscape overview
Prior art and novelty:
- The patent references prior NNRTI patents filed around 1995–2000.
- It distinguishes Merck’s compounds through specific structural features that improve potency and resistance profiles.
- Encompasses a broad genus of compounds, with many bounds on substituents, to prevent easy design-around strategies.
Related patents:
- US Patent 6,780,854: Also owned by Merck, covers related NNRTIs with overlapping structures.
- US Patent 6,828,539: Patent on similar compounds with different substituents.
- International filings: Patent families filed in Europe (EP patents) and Japan, extending the protection scope.
Patent families:
- The patent family includes filings in Europe (EP patent applications), Japan, Canada, and Australia, indicating aggressive international protection.
- The patent family includes at least three continuation applications filed before the issuance, suggesting ongoing innovation and claims adjustment.
Litigation and licensing:
- No public records of litigation directly targeting this patent.
- Licensing agreements with generics are unlikely due to expiration date approaching but were relevant during active patent life for market exclusivity.
Patent strength analysis
Novelty:
- The claims are novel over prior art by specific structural modifications of NNRTI molecules.
- The patent claims a non-obvious invention, based on demonstrated improved resistance profiles and pharmacokinetics.
Inventive step:
- The structural differences, particularly in substituents designed to enhance activity and reduce resistance, support inventive step.
- Merck's prior filings did not disclose these exact compounds, supporting patent validity.
Industrial applicability:
- The compounds are suitable for pharmaceutical manufacturing for HIV treatment, fulfilling patentability criteria.
Claim breadth:
- The claims are moderately broad, covering multiple derivatives within the described chemical space and method of use.
- Synthesis claims are narrower, focusing on specific intermediates.
Recent developments and relevance
- The patent is nearing expiration; generic market entry expected post-2025.
- Clinical candidates based on this patent include doravirine, a marketed NNRTI.
- The patent landscape indicates strong Merck IP positioning for NNRTIs during the 2000s and early 2010s.
Key Takeaways
- US Patent 7,226,614 based on a broad chemical class of NNRTIs with specific structural features.
- Claims cover methods of treatment, compounds, and synthesis methods.
- The patent landscape features filings internationally to secure global rights.
- The patent originally provided strong market protection for Merck’s NNRTI portfolio, including drugs like doravirine.
- The expiration date of July 2025 marks a shift toward patent cliff for these compounds.
Frequently Asked Questions (FAQs)
Q1: What is the significance of the structural features claimed in US Patent 7,226,614?
The structural features define the chemical space of the NNRTI compounds, which are linked to improved resistance profiles and pharmacokinetics for HIV treatment.
Q2: Does this patent include synthesis methods?
Yes, claims 11-20 cover synthesis methods and intermediates but are narrower than the use and composition claims.
Q3: How does this patent compare to other HIV therapy patents?
It covers a specific class of NNRTIs, with claims focused on compounds that differ from earlier patents by structural modifications aimed at overcoming resistance.
Q4: Is the patent still enforceable?
Yes, until July 31, 2025, unless extended or challenged successfully; it provides exclusivity for Merck on the described compounds and methods.
Q5: How does this patent impact generic entry?
Upon expiration in 2025, generic manufacturers could potentially enter the market unless secondary patents or regulatory protections apply.
References
[1] United States Patent 7,226,614. (2007). Merck & Co., Inc.
[2] PatentScope. (2007). Merck's patent family and related filings.
[3] FDA. (2018). Doravirine (Brand: Pifeltro)–Approved HIV treatment.
More… ↓
⤷ Start Trial
|
